Invention Grant
US07663018B2 Tau hyperphosphorylation in transgenic mice expressing the APP double mutation
失效
表达APP双突变的转基因小鼠中的Tau过度磷酸化
- Patent Title: Tau hyperphosphorylation in transgenic mice expressing the APP double mutation
- Patent Title (中): 表达APP双突变的转基因小鼠中的Tau过度磷酸化
-
Application No.: US11413873Application Date: 2006-04-28
-
Publication No.: US07663018B2Publication Date: 2010-02-16
- Inventor: Bernd Sommer , Matthias Stauffenbiel
- Applicant: Bernd Sommer , Matthias Stauffenbiel
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Priority: GB9615569.2 19960719; GB9711262.7 19970619
- Main IPC: A01K67/00
- IPC: A01K67/00 ; A01K67/033 ; A01K67/027 ; G01N33/00 ; C12N15/00 ; C12N5/00
Abstract:
Animal model involving transgenic manipulation of amyloid precursor protein, useful for testing potential therapeutic agents for the treatment of neurodegenerative disorders, in particular Alzheimer's disease.
Public/Granted literature
- US20070022483A1 Transgenic animal model for Alzheimer's disease Public/Granted day:2007-01-25
Information query
